ISRN hepatology最新文献_第3页

Metabolic Bone Disease in Viral Cirrhosis: A Prospective Study. 病毒性肝硬化中的代谢性骨病:一项前瞻性研究。

ISRN hepatology Pub Date : 2013-04-21 eCollection Date: 2013-01-01 DOI: 10.1155/2013/276563

Rabia Goubraim, Nawal Kabbaj, Mouna Salihoun, Zakia Chaoui, M'Hamed Nya, Naima Amrani

{"title":"Metabolic Bone Disease in Viral Cirrhosis: A Prospective Study.","authors":"Rabia Goubraim, Nawal Kabbaj, Mouna Salihoun, Zakia Chaoui, M'Hamed Nya, Naima Amrani","doi":"10.1155/2013/276563","DOIUrl":"https://doi.org/10.1155/2013/276563","url":null,"abstract":"Background/Aim. Metabolic Bone disorders are well-recognized extrahepatic complications of cirrhosis. The aim was to report their prevalence and the associated factors to their development in patients with viral cirrhosis. Patients and Methods. All consecutive patients with viral cirrhosis were prospectively enrolled. Parathyroid hormone, 25-hydroxyvitamin D, liver function, and phosphocalcic tests were measured in all patients. Bone mineral density was measured at the lumbar spine and total hip by dual-energy X-ray absorptiometry. Data were analyzed using SPSS software. Results. Forty-six cirrhotic patients were included with hepatitis C (87%) and hepatitis B (13%). The Child-Pugh score was grade A in 87% of cases and grade B in 13%. Thirty-seven patients had decreased bone mineral density with osteopenia in 24 patients and osteoporosis in 13 patients. Decreased 25-hydroxyvitamin D was found in 95.6% of cases. Bone disorders were significantly more frequent in old patients with low body mass index, long duration of liver disease, and low 25-hydroxyvitamin D level. None of these factors was an independent factor associated with bone disorders. Conclusion. Our study revealed a high prevalence of metabolic bone disorders among viral cirrhotic patients. Consequently, bone mineral density assessment should be performed systematically in all cirrhotic patients. ","PeriodicalId":91521,"journal":{"name":"ISRN hepatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2013/276563","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34719774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

Mild Hypertransaminasemia in Primary Care. 初级保健中的轻度高转氨酶血症。

ISRN hepatology Pub Date : 2013-04-10 eCollection Date: 2013-01-01 DOI: 10.1155/2013/256426

Said A Al-Busafi, Nir Hilzenrat

{"title":"Mild Hypertransaminasemia in Primary Care.","authors":"Said A Al-Busafi, Nir Hilzenrat","doi":"10.1155/2013/256426","DOIUrl":"https://doi.org/10.1155/2013/256426","url":null,"abstract":"The liver enzymes, alanine transaminase (ALT) or aspartate transaminase (AST), are commonly used in clinical practice as screening as well as diagnostic tests for liver diseases. ALT is more specific for liver injury than AST and has been shown to be a good predictor of liver related and all-cause mortality. Asymptomatic mild hypertransaminasemia (i.e., less than five times normal) is a common finding in primary care and this could be attributed to serious underlying condition or has transient and benign cause. Unfortunately, there are no good literatures available on the cost-effectiveness of evaluating patients with asymptomatic mild hypertransaminasemia. However, if the history and physical examination do not suggest a clear cause, a stepwise approach should be initiated based on pretest probability of the underlying liver disease. Nonalcoholic fatty liver disease is becoming the most common cause of mild hypertransaminasemia worldwide. Other causes include alcohol abuse, medications, and hepatitis B and C. Less common causes include hemochromatosis, α1-antitrypsin deficiency, autoimmune hepatitis, and Wilson's disease. Nonhepatic causes such as celiac disease, thyroid, and muscle disorders should be considered in the differential diagnosis. Referral to a specialist and a possible liver biopsy should be considered if persistent hypertransaminasemia for six months or more of unclear etiology. ","PeriodicalId":91521,"journal":{"name":"ISRN hepatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2013/256426","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34669733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 15

Familial Budd-Chiari Syndrome in China: A Systematic Review of the Literature. 中国家族性布-嘉氏综合征:文献系统综述。

ISRN hepatology Pub Date : 2013-02-28 eCollection Date: 2013-01-01 DOI: 10.1155/2013/763508

Xingshun Qi, Juan Wang, Weirong Ren, Ming Bai, Man Yang, Guohong Han, Daiming Fan

{"title":"Familial Budd-Chiari Syndrome in China: A Systematic Review of the Literature.","authors":"Xingshun Qi, Juan Wang, Weirong Ren, Ming Bai, Man Yang, Guohong Han, Daiming Fan","doi":"10.1155/2013/763508","DOIUrl":"https://doi.org/10.1155/2013/763508","url":null,"abstract":"Familial occurrence of Budd-Chiari syndrome (BCS) has been reported in scattered cases, which potentially favors the congenital theory. A review of the literature was conducted to demonstrate this phenomenon in China. PubMed, VIP, and CNKI databases were searched for studies describing at least two Chinese BCS patients from the same one family. In the 18 eligible papers, 30 siblings or first-degree relatives from 14 families were diagnosed with BCS at 9 different centers. Common clinical presentations included varices of abdominal wall and lower limbs, edema of legs, and ascites. Type and location of obstruction were similar among these patients from the same one family. Screening for BCS was conducted in 65 family members from 3 families, demonstrating that 2 asymptomatic siblings from one family were further diagnosed with BCS. Factor V Leiden mutation was found in 3 of 4 patients from one family and in one of 2 patients from another one family. Prothrombin G20210A gene mutation was found in none of the 4 patients from the 2 families. In conclusion, our study showed the possibility of familial aggregation in Chinese BCS patients, but these available data cannot support the previous hypothesis that familial BCS originates from congenital vascular malformation. ","PeriodicalId":91521,"journal":{"name":"ISRN hepatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2013/763508","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34603974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

The Treatment of Liver Metastases in Patients with Neuroendocrine Tumors in 2012. 2012 年神经内分泌肿瘤患者肝转移的治疗。

ISRN hepatology Pub Date : 2013-02-14 eCollection Date: 2013-01-01 DOI: 10.1155/2013/702167

Daniela Macedo, Teresa Amaral, Isabel Fernandes, Ana Rita Sousa, Ana Lúcia Costa, Isabel Távora, António Quintela, Paulo Cortes, Luís Costa

{"title":"The Treatment of Liver Metastases in Patients with Neuroendocrine Tumors in 2012.","authors":"Daniela Macedo, Teresa Amaral, Isabel Fernandes, Ana Rita Sousa, Ana Lúcia Costa, Isabel Távora, António Quintela, Paulo Cortes, Luís Costa","doi":"10.1155/2013/702167","DOIUrl":"10.1155/2013/702167","url":null,"abstract":"Neuroendocrine tumors (NETs) comprise a heterogeneous group of tumors that form a distinct entity. Approximately 75-80% of patients present with liver metastases at the time of their diagnosis, and 20%-25% will develop these lesions in the course of their disease. The presence of secondary deposits in the liver significantly increases the morbidity and mortality in these patients. The only potentially curative treatment is the surgical resection of the primary tumor and hepatic lesions. However, only 10% of patients presents under ideal conditions for that approach. Several techniques aimed at localized liver lesions have been applied also with interesting results in terms of survival and symptom control. The same has been demonstrated with new systemic therapies (target therapies). However, these are still under study, in order to define their true role in the management of these patients. This paper intends to address, in a general way, the various treatment options in patients with liver metastases from neuroendocrine tumors. ","PeriodicalId":91521,"journal":{"name":"ISRN hepatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4890909/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34603973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pathophysiological Significance of Hepatic Apoptosis. 肝细胞凋亡的病理生理学意义

ISRN hepatology Pub Date : 2012-12-30 eCollection Date: 2013-01-01 DOI: 10.1155/2013/740149

Kewei Wang, Bingliang Lin

引用次数: 0

Predictors of Developing Hepatocellular Carcinoma in Treated HCV-Carriers in Morocco according to University Hospital Experience. 根据大学医院的经验，摩洛哥治疗的hcv携带者发生肝细胞癌的预测因素。

ISRN hepatology Pub Date : 2012-12-23 eCollection Date: 2013-01-01 DOI: 10.1155/2013/438306

Younès Cherradi, Rajaa Afifi, Hanaa Benbrahim, Wafaa Essamri, Imane Benelbarhdadi, Fatima Zahra Ajana, Hadj Omar El Malki, Mustapha Benazzouz, Abdellah Essaid

{"title":"Predictors of Developing Hepatocellular Carcinoma in Treated HCV-Carriers in Morocco according to University Hospital Experience.","authors":"Younès Cherradi, Rajaa Afifi, Hanaa Benbrahim, Wafaa Essamri, Imane Benelbarhdadi, Fatima Zahra Ajana, Hadj Omar El Malki, Mustapha Benazzouz, Abdellah Essaid","doi":"10.1155/2013/438306","DOIUrl":"https://doi.org/10.1155/2013/438306","url":null,"abstract":"Introduction. Hepatitis C is the first major cause for HCC in Morocco. Antiviral treatment reduces the risk of developing HCC but few cases of HCC in HCV-treated patients were reported. We aimed to define this population's features and to identify predictive factors of developing HCC. Patients and Methods. We included all HCV carriers who developed HCC after antiviral treatment from January 2002 to April 2010. We compare HCV-treated patients with no developed HCC to HCC population using khi-2 and Fisher Exact analysis. Results. 369 HVC-treated patients were considered, and 20 HCC were reported. The risk of HCC was not significant according to gender and genotypes (resp., P = 0.63 and P = 0.87). Advanced age and severe fibrosis were significant risk factors (resp., P = 0.003 and P = 0.0001). HCC was reported in 2.6% of sustained virological responders versus 12.5% of nonresponders (P = 0.004). Conclusion. In our series, 5% of previously treated patients developed an HCC. Advanced age and severe fibrosis at HCV diagnosis are predictive factors of HCC occurrence. Sustained virological response reduces considerably the risk of HCC occurrence but screening is indicated even after SVR. ","PeriodicalId":91521,"journal":{"name":"ISRN hepatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2012-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2013/438306","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34506625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Murine Models of Nonalcoholic Fatty Liver Disease and Steatohepatitis. 非酒精性脂肪性肝病和脂肪性肝炎小鼠模型。

ISRN hepatology Pub Date : 2012-12-12 eCollection Date: 2013-01-01 DOI: 10.1155/2013/237870

Masashi Ninomiya, Yasuteru Kondo, Tooru Shimosegawa

引用次数: 6

The Role of Interventional Radiology in Treating Complications following Liver Transplantation. 介入放射学在肝移植术后并发症治疗中的作用。

ISRN hepatology Pub Date : 2012-12-03 eCollection Date: 2013-01-01 DOI: 10.1155/2013/696794

Homoyoon Mehrzad, Kamarjit Mangat

引用次数: 6

Quantifying Serum Level of Glycochenodeoxycholic Acid Using High Performance Liquid Chromatography in Obstructive Jaundice Patients. 高效液相色谱法定量测定梗阻性黄疸患者血清糖鹅脱氧胆酸水平。

ISRN hepatology Pub Date : 2012-11-05 eCollection Date: 2013-01-01 DOI: 10.1155/2013/508368

Toar J M Lalisang, Metta Sinta Sari Wiria, Vivian Sutikno, Melva Louisa, Arie Estuningtyas

{"title":"Quantifying Serum Level of Glycochenodeoxycholic Acid Using High Performance Liquid Chromatography in Obstructive Jaundice Patients.","authors":"Toar J M Lalisang, Metta Sinta Sari Wiria, Vivian Sutikno, Melva Louisa, Arie Estuningtyas","doi":"10.1155/2013/508368","DOIUrl":"https://doi.org/10.1155/2013/508368","url":null,"abstract":"Introduction. Accumulation of glycochenodeoxycholic acid (GCDC) in serum has a clinical significance as an inductor of pathological hepatocyte apoptosis, which impairs liver function. Inhibition of GCDC accumulation can be used as a marker in therapy. This study was aimed to quantify the serum level of GCDC in obstructive jaundice patients. Methodology. GCDC acid level in the serum was quantified using high performance liquid chromatography (HPLC) technique according to Muraca and Ghoos modified method. It was performed before and after decompression at day 7 and day 14. The sample was extracted with solid phase extraction (SPE) technique on SPE column. The results were analyzed using SPSS V 16.0 (P < 0.05) and quantified with standard curve on GCDC acid. Result. There were 21 cases with range of GCDC acid serum level before decompression was 90.9 (SD 205.5) μmol/L and day 7 after decompression decreased to 4.0 (SD 46.4) μmol/L and then increased to 11.3 (SD 21.9) μmol/L (P < 0.05). This method could separate GCDC acid on serum with good resolution, high precision and accuracy, and linear calibration curve on measured level range. Conclusion. HPLC can quantify GCDC acid serum on obstructive jaundice patients and can be used to support its pharmacokinetic study. ","PeriodicalId":91521,"journal":{"name":"ISRN hepatology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2012-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2013/508368","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34669728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0